Because inhibiting CXCR4 or CXCR7 only on 231-control cancer cells did not affect adhesion, these data further emphasize that basal treatment with CXCL12 acts through endothelial CXCR4 to significantly enhance adhesion of circulating cancer cells. Here, CXCR4 is linked to cancer.